
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it ...
Log in to your account.
Start your free account.
9 articles · updated every 3 minutes

The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it ...

OpenAI's acquisition could revolutionize drug development, potentially reducing timelines and increasing efficiency in the pharmaceutical industry. Th...

AI watermarking in protein design could enhance biosecurity by ensuring traceability and authenticity, crucial for synthetic biology's future. The pos...

AI-driven antibody design could revolutionize drug development, potentially accelerating timelines and enhancing precision in targeting diseases. The ...

Braveheart Bio's IPO success highlights strong investor appetite for biotech innovation, despite risks of high valuations without revenue. The post Br...

The shift towards decentralized science models like Bio Protocol could democratize research funding, accelerating innovation and reducing bureaucracy....

OpenAI's enhanced bounty program underscores the growing importance of robust AI security measures, potentially setting industry standards. The post O...
In a Brazilian Congress hearing, Fábio Araújo, consultant for the Financial System Regulation Department (Denor), stressed that, unlike other crypto a...

AI-driven decentralization in biotech research could revolutionize scientific collaboration, enhancing efficiency and accountability in innovation. Th...